Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - telmisartan, quantity: 40 mg; amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg) - tablet, multilayer - excipient ingredients: colloidal anhydrous silica; sodium hydroxide; sorbitol; magnesium stearate; pregelatinised maize starch; povidone; microcrystalline cellulose; maize starch; meglumine; colour - treatment of hypertension. treatment should not be initiated with this fixed-dose combination. (see dosage and administration)

Ireland - English - HPRA (Health Products Regulatory Authority)

teva b.v. - olmesartan medoxomil, amlodipine besilate - film coated tablet - 20/5 mg/mg - angiotensin ii antagonists and calcium channel blockers

Ireland - English - HPRA (Health Products Regulatory Authority)

teva b.v. - olmesartan medoxomil, amlodipine besilate - film coated tablet - 40/5 - angiotensin ii antagonists and calcium channel blockers

Ireland - English - HPRA (Health Products Regulatory Authority)

teva b.v. - olmesartan medoxomil, amlodipine besilate - film coated tablet - 40/10 - angiotensin ii antagonists and calcium channel blockers

Malta - English - Medicines Authority

alkaloid-int d.o.o. Šlandrova ulica 4, 1231 ljubljana-crnuce, slovenia - lisinopril, amlodipine - tablet - lisinopril 10 mg amlodipine 5 mg - agents acting on the renin-angiotensin system

Malta - English - Medicines Authority

alkaloid-int d.o.o. Šlandrova ulica 4, 1231 ljubljana-crnuce, slovenia - lisinopril, amlodipine - tablet - lisinopril 20 mg amlodipine 10 mg - agents acting on the renin-angiotensin system

Malta - English - Medicines Authority

alkaloid-int d.o.o. Šlandrova ulica 4, 1231 ljubljana-crnuce, slovenia - lisinopril, amlodipine - tablet - lisinopril 20 mg amlodipine 5 mg - agents acting on the renin-angiotensin system

United States - English - NLM (National Library of Medicine)

bluepoint laboratories - ramipril (unii: l35jn3i7sj) (ramiprilat - unii:6n5u4qfc3g) - ramipril 1.25 mg - ramipril capsules, usp are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug.ramipril capsules, usp are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one dr

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - ramipril (unii: l35jn3i7sj) (ramiprilat - unii:6n5u4qfc3g) - ramipril 1.25 mg - ramipril is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms

United States - English - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - ramipril (unii: l35jn3i7sj) (ramiprilat - unii:6n5u4qfc3g) - ramipril 1.25 mg - ramipril capsules are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic classes and with different